Ash Access Technology, Inc. Led by the visionary nephrologist, Dr. Stephen R.

Ash, and driven by CEO Robert B. Truitt, the company has consistently delivered innovative and effective solutions for patients worldwide. Many of their technologies and products have set the industry standard, with some being spun out into new companies or acquired by others.

Ash Access Technology offers a diverse range of breakthrough products. Their licensed products and technologies include ZuraGard™ Skin Prep, which provides antimicrobial surgical skin prep, as well as the Centros® Catheters that eliminate catheter failures. They also offer novel catheter lock solutions, such as the 7% Sodium Citrate Catheter Locks, which maintain catheter patency.

One of their most notable achievements is the development of the Biologic-DT™ Liver Dialysis Unit™, the first FDA-approved liver support device for treating liver failure and drug overdose. Currently, Ash Access Technology's subsidiary, HemoCleanse Technologies, LLC, is continuing research and development in sorbent and vascular access innovations. Their ongoing projects include an oral sorbent medication, improved needle insertion methods for dialysis therapy, a new type of vascular access for dialysis, and enhanced designs for peritoneal dialysis catheters.

Ash Access Technology has positively impacted the lives of millions of patients worldwide, providing safer and more comfortable products that improve the quality of life for both patients and their families. Their commitment to making a difference in the medical field is truly commendable